Archford Capital Strategies LLC Has $1.53 Million Stock Position in Bristol-Myers Squibb Co (NYSE:BMY)

Archford Capital Strategies LLC raised its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 0.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,810 shares of the biopharmaceutical company’s stock after buying an additional 189 shares during the quarter. Archford Capital Strategies LLC’s holdings in Bristol-Myers Squibb were worth $1,528,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Bristol-Myers Squibb by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 134,058,636 shares of the biopharmaceutical company’s stock worth $6,079,559,000 after buying an additional 1,580,750 shares during the period. BlackRock Inc. lifted its position in shares of Bristol-Myers Squibb by 6.7% during the 2nd quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock worth $5,206,108,000 after buying an additional 7,178,698 shares during the period. Invesco Ltd. lifted its position in shares of Bristol-Myers Squibb by 40.4% during the 2nd quarter. Invesco Ltd. now owns 24,012,686 shares of the biopharmaceutical company’s stock worth $1,088,974,000 after buying an additional 6,915,526 shares during the period. Price T Rowe Associates Inc. MD raised its position in Bristol-Myers Squibb by 42.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 12,749,545 shares of the biopharmaceutical company’s stock valued at $578,192,000 after purchasing an additional 3,816,247 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its stake in shares of Bristol-Myers Squibb by 14,860.1% in the 2nd quarter. Nuveen Asset Management LLC now owns 9,395,120 shares of the biopharmaceutical company’s stock valued at $426,069,000 after buying an additional 9,332,319 shares during the period. Institutional investors own 83.02% of the company’s stock.

BMY has been the subject of a number of analyst reports. ValuEngine raised Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research note on Tuesday, November 19th. Mizuho began coverage on Bristol-Myers Squibb in a research note on Monday, November 25th. They set a “buy” rating for the company. Argus upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $80.00 target price on the stock in a report on Friday, December 13th. Morgan Stanley began coverage on Bristol-Myers Squibb in a report on Friday, November 22nd. They set an “equal weight” rating and a $60.00 target price on the stock. Finally, Citigroup upgraded Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $73.00 target price on the stock in a report on Monday, January 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and fourteen have given a buy rating to the company. Bristol-Myers Squibb has an average rating of “Buy” and an average target price of $61.69.

Shares of Bristol-Myers Squibb stock opened at $66.44 on Wednesday. The firm has a market cap of $106.28 billion, a price-to-earnings ratio of 16.69, a price-to-earnings-growth ratio of 0.84 and a beta of 0.73. The stock’s 50-day moving average is $62.32 and its 200-day moving average is $52.93. Bristol-Myers Squibb Co has a one year low of $42.48 and a one year high of $66.99. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.83 and a quick ratio of 3.72.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, beating analysts’ consensus estimates of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The company had revenue of $6.01 billion for the quarter, compared to analyst estimates of $5.89 billion. During the same period in the previous year, the company posted $1.09 earnings per share. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. On average, equities analysts expect that Bristol-Myers Squibb Co will post 4.47 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be issued a dividend of $0.45 per share. This represents a $1.80 annualized dividend and a yield of 2.71%. The ex-dividend date is Thursday, January 2nd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. Bristol-Myers Squibb’s dividend payout ratio is presently 45.23%.

In related news, SVP John E. Elicker sold 15,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total transaction of $849,900.00. Following the sale, the senior vice president now owns 74,471 shares in the company, valued at $4,219,526.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Louis S. Schmukler sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the transaction, the insider now directly owns 31,963 shares in the company, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. Corporate insiders own 0.13% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: What member countries make up the G-20?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.